Table 2.

Clinical factors associated with mild disease activity or remission at week 52

	Corticosteroid use at wk 8 n = 85a			Response at wk 12 (SCCAI <5) n = 73b			Remission at wk 12 (SCCAI ≤2) N = 73b
	Yes n = 25	No n = 57	P value	Yes n = 57	No n = 14	P value	Yes n = 38	No n = 33	P value
Response at wk 52 (SCCAI < 5) n = 44	36%	60%	0.05	70%	29%	0.004	71%	50%	0.01
Remission at wk 52 (SCCAI ≤2) n = 32	24%	46%	0.07	51%	21%	0.05	53%	35%	0.03

Response was defined as mild or no clinical disease activity at the time point of evaluation and remission as no disease activity at the time point of evaluation.

Other factors not associated with mild disease activity or remission at week 52 included the following: Mayo endoscopic score 3 vs ≥3 at baseline, <2 vs ≥2 previous biologic failures before initiation of tofacitinib, mild disease activity (SCCAI <5) or remission status (SCCAI ≤2) at week 8 or corticosteroid use at week 12.

SCCAI, simple clinical colitis activity index.

^a85 patients in the study, but for 3 patients, steroid use was not known at week 8.

^b73 patients in the study, but for 2 patients, SCCAI values were not known in the predefined time frame week 12.